Author:
Rosas-Alonso Rocío,Colmenarejo-Fernández Julian,Pernía Olga,Burdiel Miranda,Rodríguez-Antolín Carlos,Losantos-García Itsaso,Rubio Tania,Moreno-Velasco Rocío,Esteban-Rodríguez Isabel,Martínez-Marín Virginia,Yubero Paloma,Costa-Fraga Nicolas,Díaz-Lagares Angel,López-López Rafael,Díaz-Martin Eva,García Juan F.,Sánchez Catalina Vivancos,Gandía-González Maria Luisa,Moreno-Bueno Gema,de Castro Javier,de Cáceres Inmaculada Ibánez
Abstract
AbstractGlioblastoma (GB) is a devastating tumor of the central nervous system characterized by a poor prognosis. One of the best-established predictive biomarker in IDH-wildtype GB is O6-methylguanine-DNA methyltransferase (MGMT) methylation (mMGMT), which is associated with improved treatment response and survival. However, current efforts to monitor GB patients through mMGMT detection have proven unsuccessful. Small extracellular vesicles (sEVs) hold potential as a key element that could revolutionize clinical practice by offering new possibilities for liquid biopsy. This study aimed to determine the utility of sEV-based liquid biopsy as a predictive biomarker and disease monitoring tool in patients with IDH-wildtype GB. Our findings show consistent results with tissue-based analysis, achieving a remarkable sensitivity of 85.7% for detecting mMGMT in liquid biopsy, the highest reported to date. Moreover, we suggested that liquid biopsy assessment of sEV-DNA could be a powerful tool for monitoring disease progression in IDH-wildtype GB patients. This study highlights the critical significance of overcoming molecular underdetection, which can lead to missed treatment opportunities and misdiagnoses, possibly resulting in ineffective therapies. The outcomes of our research significantly contribute to the field of sEV-DNA-based liquid biopsy, providing valuable insights into tumor tissue heterogeneity and establishing it as a promising tool for detecting GB biomarkers. These results have substantial implications for advancing predictive and therapeutic approaches in the context of GB and warrant further exploration and validation in clinical settings.
Funder
Instituto de Salud Carlos III
GHETTI
Ministerio de Ciencia e Innovación
Publisher
Springer Science and Business Media LLC
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献